Both
serum and urine samples were positive (scores of 1 or 2) when the dot-blot assay was done during the active phase. After 3 months of treatment in hospital, both serum and urine samples showed weaker reactions. Subsequently, both serum and urine became negative, suggesting that the disease had become inactive. When we compared dot-blot assay results of samples from infected and uninfected subjects, the mean value for serum samples from infected subjects was 1.14, which was significantly higher than the mean value of 0.15 for those from uninfected subjects (Fig. 5). The mean assay value for serum samples from patients with active disease was 1.43, which was also significantly higher than that for those from patients with inactive disease (0.93). Thus, dot-blot Protein Tyrosine Kinase inhibitor Palbociclib assay using MPB64 antigen produced a significantly higher frequency of positive results with infected serum samples than with uninfected serum samples; it also produced a significantly higher frequency of positive results with serum samples from active
disease than with those from inactive disease. The sensitivity and specificity of this assay for serum samples was 85.7% and 85.0%, respectively. The mean dot-blot assay value for infected urine samples was 0.96, which was significantly higher than the mean value of 0.2 for uninfected urine samples. The mean value for urine samples from patients with active disease was 1.36, which was also significantly higher than the mean value of 0.56 for those from inactive disease. Thus, the dot-blot assay using MPB64 antigen yielded a significantly higher frequency of positive results with urine samples from infected patients than with those from uninfected individuals. In addition, this test was positive significantly more frequently for samples from patients with active disease than for samples
from those with inactive disease. The sensitivity and specificity of this assay for 4-Aminobutyrate aminotransferase urine samples was 75.0% and 85.0%, respectively. We combined and compared data for serum samples from uninfected individuals and TB patients with active or inactive disease with urine data to assess any correlations between them (Fig. 6). All the serum and urine samples that showed strong reactions (rated as “2”) were from patients with active disease. Serum or urine samples from all patients with active disease showed positive reactions (“1” or “2”) on dot-blot assay. None of the serum and urine samples from uninfected subjects showed strong reactions and only a few displayed weak reactions. All the serum and urine samples from patients with inactive disease were also negative or weakly positive. When we compared data from urine and serum specimens, we found a strong correlation between the results for both specimens (n = 34, r = 0.672). In many countries, the diagnosis of TB still relies on chest X-ray films and Ziehl-Neelsen staining of sputum specimens.